Clinical Trials Logo

Palmoplantar Pustulosis clinical trials

View clinical trials related to Palmoplantar Pustulosis.

Filter by:

NCT ID: NCT05194839 Recruiting - Clinical trials for Palmoplantar Pustulosis

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Start date: January 5, 2022
Phase: Phase 2
Study type: Interventional

A 12-week Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis followed by an Open-label Extension Phase.

NCT ID: NCT05174065 Recruiting - Clinical trials for Palmoplantar Pustulosis

Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)

Start date: March 8, 2022
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the efficacy of apremilast (AMG 407) twice daily (BID) compared with placebo in participants with Palmoplantar Pustulosis (PPP).

NCT ID: NCT04572997 Completed - Clinical trials for Palmoplantar Pustulosis

Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS)

APLANTUS
Start date: November 29, 2018
Phase: Phase 2
Study type: Interventional

Multicenter, open-label, single-arm, phase II, pilot study. The screening period was up to 4 weeks and treatment took place over 20 weeks per patient. Five visits per patient were performed including: Visit 1 at week -4 to -1 (screening), Visit 2 at week 0 (baseline), Visit 3 at week 4, Visit 4 at week 12, and Visit 5 at week 20 (end of study). There was no follow-up period.

NCT ID: NCT04566471 Active, not recruiting - Clinical trials for Palmoplantar Pustulosis

Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence

Start date: January 1, 2012
Phase:
Study type: Observational

This study plans to calculate the prevalence and incidence of palmoplantar pustulosis and generalized pustular psoriasis based on the national medical insurance data and analyze the composition characteristics and some clinical features of patients, through taking into account of the research status of palmoplantar pustulosis and generalized pustular psoriasis and the characteristics of medical insurance data.

NCT ID: NCT04493424 Recruiting - Clinical trials for Palmoplantar Pustulosis

A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab

Start date: September 4, 2020
Phase: Phase 2
Study type: Interventional

This study is open to people with palmoplantar pustulosis who took part in previous clinical studies of a medicine called spesolimab. Participants who benefited from spesolimab treatment in the previous studies can join this study. The purpose of this study is to find out how safe spesolimab is and whether it helps people with palmoplantar pustulosis in the long-term. Participants are in this study for up to 5 years. During this time they visit the study site every month to get spesolimab injections under the skin. At study visits, doctors check the severity of participants' palmoplantar pustulosis and collect information on any health problems of the participants.

NCT ID: NCT04459507 Recruiting - Clinical trials for Palmoplantar Pustulosis

A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan

ProPuP
Start date: March 22, 2021
Phase:
Study type: Observational

The purpose of this study is to describe the treatment patterns of participants receiving systemic treatment for of palmoplantar pustulosis (PPP) in Japan.

NCT ID: NCT04061252 Active, not recruiting - Clinical trials for Palmoplantar Pustulosis

A Study of KHK4827 in Subjects With Palmoplantar Pustulosis

Start date: August 10, 2019
Phase: Phase 3
Study type: Interventional

Evaluation of efficacy and safety of KHK4827 in Subjects with Palmoplantar Pustulosis

NCT ID: NCT03988335 Completed - Clinical trials for Palmoplantar Pustulosis

A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Start date: February 13, 2019
Phase: Phase 2
Study type: Interventional

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis

NCT ID: NCT03972280 Active, not recruiting - Clinical trials for Hidradenitis Suppurativa

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

Start date: July 4, 2019
Phase: Phase 1
Study type: Interventional

Study CSL324_1002 will investigate the safety and pharmacokinetics of repeat doses of CSL324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis. CSL324 is a novel, recombinant therapy that may treat diseases caused by increased numbers of neutrophils at sites of inflammation.

NCT ID: NCT03633396 Completed - Clinical trials for Palmoplantar Pustulosis

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis

POPLAR
Start date: May 20, 2019
Phase: Phase 2
Study type: Interventional

A study to evaluate the efficacy and safety, and pharmacokinetic (PK) profile of multiple doses of imsidolimab (ANB019) in adults with palmoplantar pustulosis (PPP)